FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer

por Liu, Cassie, Barger, Carter J., Karpf, Adam R.
Publicado 2021

Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer

por Barger, Carter J, Branick, Connor, Chee, Linda, Karpf, Adam R.
Publicado 2019

DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer

por Zhang, Wa, Barger, Carter J, Link, Petra A, Mhawech-Fauceglia, Paulette, Miller, Austin, Akers, Stacey N, Odunsi, Kunle, Karpf, Adam R
Publicado 2015

Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression

por Barger, Carter J., Zhang, Wa, Hillman, Joanna, Stablewski, Aimee B., Higgins, Michael J., Vanderhyden, Barbara C., Odunsi, Kunle, Karpf, Adam R.
Publicado 2015

Global DNA Hypomethylation in Epithelial Ovarian Cancer: Passive Demethylation and Association with Genomic Instability

por Zhang, Wa, Klinkebiel, David, Barger, Carter J., Pandey, Sanjit, Guda, Chittibabu, Miller, Austin, Akers, Stacey N., Odunsi, Kunle, Karpf, Adam R.
Publicado 2020

PRAME expression and promoter hypomethylation in epithelial ovarian cancer

por Zhang, Wa, Barger, Carter J., Eng, Kevin H., Klinkebiel, David, Link, Petra A., Omilian, Angela, Bshara, Wiam, Odunsi, Kunle, Karpf, Adam R.
Publicado 2016

NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma

por Haque, Moinul, Li, Jing, Huang, Yung-Hsing, Almowaled, Meaad, Barger, Carter J., Karpf, Adam R., Wang, Peng, Chen, Will, Turner, Suzanne D., Lai, Raymond
Publicado 2019

Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer

por Barger, Carter J, Chee, Linda, Albahrani, Mustafa, Munoz-Trujillo, Catalina, Boghean, Lidia, Branick, Connor, Odunsi, Kunle, Drapkin, Ronny, Zou, Lee, Karpf, Adam R
Publicado 2021

Hyperpolarized δ-[1- (13)C]gluconolactone imaging visualizes response to TERT or GABPB1 targeting therapy for glioblastoma

por Minami, Noriaki, Hong, Donghyun, Taglang, Celine, Batsios, Georgios, Gillespie, Anne Marie, Viswanath, Pavithra, Stevers, Nicholas, Barger, Carter J., Costello, Joseph F., Ronen, Sabrina M.
Publicado 2023

Expression of the POTE gene family in human ovarian cancer

por Barger, Carter J, Zhang, Wa, Sharma, Ashok, Chee, Linda, James, Smitha R., Kufel, Christina N., Miller, Austin, Meza, Jane, Drapkin, Ronny, Odunsi, Kunle, Klinkebiel, David, Karpf, Adam R.
Publicado 2018

Conserved features of TERT promoter duplications reveal an activation mechanism that mimics hotspot mutations in cancer

por Barger, Carter J., Suwala, Abigail K., Soczek, Katarzyna M., Wang, Albert S., Kim, Min Y., Hong, Chibo, Doudna, Jennifer A., Chang, Susan M., Phillips, Joanna J., Solomon, David A., Costello, Joseph F.
Publicado 2022

CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax

por Kour, Smit, Rana, Sandeep, Contreras, Jacob I., King, Hannah M., Robb, Caroline M., Sonawane, Yogesh A., Bendjennat, Mourad, Crawford, Ayrianne J., Barger, Carter J., Kizhake, Smitha, Luo, Xu, Hollingsworth, Michael A., Natarajan, Amarnath
Publicado 2019

Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

por Robb, Caroline M., Kour, Smit, Contreras, Jacob I., Agarwal, Ekta, Barger, Carter J., Rana, Sandeep, Sonawane, Yogesh, Neilsen, Beth K., Taylor, Margaret, Kizhake, Smitha, Thakare, Rhishikesh N., Chowdhury, Sanjib, Wang, Jing, Black, Jennifer D., Hollingsworth, Michael A., Brattain, Michael G., Natarajan, Amarnath
Publicado 2017

Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

por Robb, Caroline M., Kour, Smit, Contreras, Jacob I., Agarwal, Ekta, Barger, Carter J., Rana, Sandeep, Sonawane, Yogesh, Neilsen, Beth K., Taylor, Margaret, Kizhake, Smitha, Thakare, Rhishikesh N., Chowdhury, Sanjib, Wang, Jing, Black, Jennifer D., Hollingsworth, Michael A., Brattain, Michael G., Natarajan, Amarnath
Publicado 2020

CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models

por Xu, Haineng, George, Erin, Kinose, Yasuto, Kim, Hyoung, Shah, Jennifer B., Peake, Jasmine D., Ferman, Benjamin, Medvedev, Sergey, Murtha, Thomas, Barger, Carter J., Devins, Kyle M., D’Andrea, Kurt, Wubbenhorst, Bradley, Schwartz, Lauren E., Hwang, Wei-Ting, Mills, Gordon B., Nathanson, Katherine L., Karpf, Adam R., Drapkin, Ronny, Brown, Eric J., Simpkins, Fiona
Publicado 2021